Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 21540237)

  • 1. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.
    Torres KE; Zhu QS; Bill K; Lopez G; Ghadimi MP; Xie X; Young ED; Liu J; Nguyen T; Bolshakov S; Belousov R; Wang S; Lahat G; Liu J; Hernandez B; Lazar AJ; Lev D
    Clin Cancer Res; 2011 Jun; 17(12):3943-55. PubMed ID: 21540237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells.
    Shintani T; Kusuhara Y; Daizumoto K; Dondoo TO; Yamamoto H; Mori H; Fukawa T; Nakatsuji H; Fukumori T; Takahashi M; Kanayama H
    Urology; 2017 Mar; 101():169.e7-169.e13. PubMed ID: 28013036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Calizo A; Pratilas CA
    Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro.
    Su W; Gutmann DH; Perry A; Abounader R; Laterra J; Sherman LS
    Glia; 2004 Feb; 45(3):297-306. PubMed ID: 14730703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.
    Ghadimi MP; Young ED; Belousov R; Zhang Y; Lopez G; Lusby K; Kivlin C; Demicco EG; Creighton CJ; Lazar AJ; Pollock RE; Lev D
    Clin Cancer Res; 2012 May; 18(9):2545-57. PubMed ID: 22407831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
    Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
    Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
    Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
    Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
    Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
    Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.
    Ghadimi MP; Lopez G; Torres KE; Belousov R; Young ED; Liu J; Brewer KJ; Hoffman A; Lusby K; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2012 Aug; 11(8):1758-69. PubMed ID: 22848094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
    Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
    Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
    Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
    Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
    Sameni M; Tovar EA; Essenburg CJ; Chalasani A; Linklater ES; Borgman A; Cherba DM; Anbalagan A; Winn ME; Graveel CR; Sloane BF
    Clin Cancer Res; 2016 Feb; 22(4):923-34. PubMed ID: 26432786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
    Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N
    Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
    Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
    Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
    Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.
    Mahller YY; Vaikunth SS; Currier MA; Miller SJ; Ripberger MC; Hsu YH; Mehrian-Shai R; Collins MH; Crombleholme TM; Ratner N; Cripe TP
    Mol Ther; 2007 Feb; 15(2):279-86. PubMed ID: 17235305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling.
    Parr C; Ali AY
    J Transl Med; 2018 Oct; 16(1):281. PubMed ID: 30314527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
    Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
    Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.